

NEONATAL MEDICATION PROTOCOLS

NYSTATIN
 Created by: NCCU
 Date revised: Dec 2014;Feb 2016
 Date for review: Feb 2019

NCCU Clinical Guidelines
 KEMH/PMH
 Perth, Western Australia

DRUG:	NYSTATIN
ALERTS & RESTRICTIONS:	Antimicrobial Restriction: Category A GREEN Unrestricted
PRESENTATION:	Suspension: 100,000 units/mL Cream or Ointment: 100,000 unit/g
ACTION & INDICATION:	Antifungal agent. For prophylaxis of systemic candida, or treatment of topical and oral candida infections. Prophylaxis for all infants who meet the following criteria: <ul style="list-style-type: none"> • All infants ≤ 32 w GA with central line(s), including UAC/UVC, long line, femoral line, Broviac • All infants on TPN • All infants on ventilation or CPAP • Infants with tracheostomies until discharge from NCCU • During antibiotic therapy and until 48 hours* after completion of course Note: Nystatin is not required for <ul style="list-style-type: none"> • Term infants (unless >5d antibiotic therapy) • Infants on postnatal wards or for infants being discharged home or back transferred before 48 hours after antibiotic course completed).
DOSE:	Prophylaxis: Oral suspension 1mL three times a day Treatment: Oral suspension 1mL 6 hourly AND Nystatin cream or ointment topically at each nappy change
ADMINISTRATION:	Half the required dose will be applied to the oral mucosa and half given via the oro/naso gastric tube followed by 0.3mL of sterile water. If the neonate has a coordinated suck / swallow reflex then the oral dose may be given orally via a syringe or teat. May be given to infants NBM
REFERENCES:	Paediatric Pharmacopoeia 13th Ed Royal Women's Hospital Melbourne Blyth CC et al. Chemoprophylaxis of neonatal fungal infections in very low birth weight infants: efficacy and safety of fluconazole and nystatin. Journal of Paediatrics and Child Health 2012 Nov; 48(9):846-51.